Find a Tender
complete
Official procurement procedure
Aseptic Workstation with integrated Hydrogen Peroxide Vapour (HPV) decontamination equipment for the use in the manufacture of gene therapy drugs/treatments for research and development, education/teaching and training.
Biomedical equipment
Installation services of laboratory equipment
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Sheffield Hallam University: "Aseptic Workstation with integrated Hydrogen Peroxide Vapour (HPV) decontamination equipment for the use in the manufacture of gene therapy drugs/treatments for research and development, education/teaching and training.". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | Sheffield Hallam University | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: Sheffield Hallam University
Market Analytics
Derived from OCDS awards & bid statistics
Published history for Sheffield Hallam University. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Competition Density
4.2Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 9 active published awards; 9 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthoritySheffield Hallam University | Procedure methodNot published | Procurement categoryNot published |
Statuscomplete | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published28 Feb 2023, 15:45 GMT | Last source update28 Feb 2023, 15:45 GMT | Recurring procurementNot published |
ClassificationBiomedical equipment, Installation services of laboratory equipment | ||
Delivery area | ||
OCIDocds-h6vhtk-039927 | ||
What is being bought
The University of Sheffield (UoS) is establishing a new 'Gene Therapy Innovation Manufacturing Centre' (GTIMC) to advance scientific discoveries into life-changing treatments for patients with life threatening diseases. The Sheffield GTIMC will be one of three cutting edge hubs in the UK dedicated to advancing the clinical development of new genetic treatments. This facility opened in the Summer of 2022 and further details can be found at the following link: -
https://www.sheffield.ac.uk/news/new-gene-therapy-innovation-centre-advance-scientific-discoveries-life-changing-treatments
The UoS requires a Modular Isolator with integrated Hydrogen Peroxide Vapour (HPV) decontamination capability in order to undertake this co-ordinated work in parallel to other UK site - NHS Blood and Transplant (Bristol) working on identical methods and processes. To ensure the consistency of the science and comparability of the process development and results, the same equipment needs to be purchased as the other hub at NHSBT. GTIMC and NHSBT Hubs will use the same manufacturing platform being tech transferred from Cell and Gene Therapy Catapult.
What changed
From the official release history
- Official notice release published
28 Feb 2023, 15:45 GMT - Status changed to complete
20 Jan 2023, 10:10 GMT - Official notice release published
20 Jan 2023, 10:10 GMT - Buyer information updated
20 Jan 2023, 10:10 GMT
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedcancelledPublished valueNot publishedIn order to assist with the tech transfer from Catapult the following item is being purchased asap: 1 x Bioquell QUBE Modular Aseptic Workstation with integrated Hydrogen Peroxide Vapour (HPV) decontamination and 1 x Bioquell QUBE System - M-35 The above equipment will be used to furnish two clean rooms. Installation, commissioning, consumables and trainingContract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
28 Feb 2023, 15:45 GMT - Award active
Not published · Not published - Contract active
Signed 7 Feb 2023, 00:00 GMT · Not published
Commercial outcome and competition
Awards ECOLAB LIMITED Not published · Not published · active |
Contracts Contract Not published · signed 7 Feb 2023, 00:00 GMT · active |
Bid statistics highestValidBidValue: 300000 lowestValidBidValue: 120000 bids: 1 (lot 1) highestValidBidValue: 300000 (lot 1) lowestValidBidValue: 120000 (lot 1) |
Buyer and organisations in this procedure
Sheffield Hallam University
Contracting authority GB-UKPRN-10007157Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published
Planning and rationale
Planning budgetNot published |
No-engagement rationaleNot published |
Procedure rationaleThe University of Sheffield signed an agreement with Cell and Gene Therapy Catapult (CGT Catapult) to tech transfer the Catapult AAV (Adeno-Associated Virus) manufacturing platform to Gene Therapy Innovation and Manufacturing Centre' (GTIMC). This task is one of the milestones under the funding award supporting the establishment of the GTIMC in Sheffield. The milestone must be completed asap. Any delay in the tech transfer will also impact on the milestone related to MHRA accreditation of GTIMC due by end Q4 2023.
Using exactly the same equipment as the set up at Cell and Gene Therapy Catapult facilities will minimise delays and reduce time/avoid the need for optimisation of manufacturing protocols at GTIMC and allow us timely and within budget achievement of tech transfer milestones, optimisation using non generic equipment may introduce inconsistent results and invalidate the process which as a result would delay process, characterisation and final production processes.
The GTIMC and University of Sheffield will jointly acquire a technology license from CGT Catapult to be able to use their AAV manufacturing platform. This platform was established and optimised based on the processes developed using the proposed list of equipment.
A single source is therefore proposed to formalise the solution provided by ECOLAB LTD for the following reasons: -
This equipment has been identified and is currently used by CGT Catapult and therefore to not use the same equipment would invalidate the Tech Transfer processes and agreements
Furthermore, this specific equipment and supplier was identified by CGT Catapult as the optimum type to produce the results and treatments for the better advancement of the process, deviation from this would require significant lengthy additional optimisation which would significantly delay the process and miss funding milestones and therefore minimise delays and reduce time/avoid the need for optimisation of manufacturing protocols at GTIMC and allow us timely and within budget achievement of tech transfer milestones, optimisation using different equipment may introduce inconsistent results and invalidate the process which as a result would delay process, characterisation and final production processes.
Finally, the equipment set out herein will purely for the purpose of research, experiment, study or development within the University and no commercial licence will be held during the lifespan of this equipment. The prime functions of the GTIMC hub is to accelerate translational of gene therapy programs and clinical trials for rare monogenic diseases.
To increase the U.K. capacity for GMP clinical vector manufacturing using the catapult process to allow for expansion of U.K. skills and training within the GTIMC space and increase partnerships with other academia which will create a fertile ecosystem for innovation and research excellence in this field across academia. |